机构:[1]School of Medicine, Kunming University of Science and Technology, Affiliated by The First People's Hospital of Yunnan Province, Kunming 650504, Yunnan, China.云南省第一人民医院[2]Yunnan Digestive Endoscopy Clinical Medical Center, Gastroenterology Department, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan, China.内科片消化内科云南省第一人民医院[3]Clinical Laboratory of Integrative Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, Liaoning, China.大连医科大学附属第一医院[4]General Surgery Department, The Second Affiliated Hospital of Harbin Medical University, Harbin 150086, Heilongjiang, China.[5]Ophthalmology Department, Jiangxi Provincial People's Hospital, Nanchang 330006, Jiangxi, China.
GDP Dissociation inhibitor 2 (GDI2) gene has been correlated with some important biological processes in a variety of cancers, whereas the role of GDI2 in hepatocellular carcinoma (HCC) is ill-defined. We aimed to demonstrate the relationship between GDI2 and HCC based on The Cancer Genome Atlas (TCGA) data mining.The expression of GDI2 was compared between cancer and normal tissues of 371 HCC patients collected from TCGA-LIHC, and verified in HCC cell lines. Gene set enrichment analysis (GSEA) was applied to annotate biological function of GDI2. Furthermore, Wilcoxon rank sum test, Logistics regression, as well as Cox regression and Kaplan-Meier survival analysis, were employed to evaluate the association of GDI2 expression with clinicopathological characteristics, and survival status of HCC patients, respectively.It showed that the expression of GDI2 was much higher in tumor tissues than in normal tissues (P < 0.001) of HCC patients. And the elevated expression of GDI2 was correlated with more aggressive HCC tumor status, including severe primary tumor extent, advanced pathological stage, serious histologic grade, and mutated TP53 status (P < 0.05). Moreover, high GDI2 expression was strongly associated with a poor survival rate (P < 0.001). Both enrichment and immune infiltration analyses implied that GDI2-associated signaling mainly involve lipid metabolism and extracellular matrix (ECM) constructing pathways related to tumor microenvironment (TME) (P < 0.05).The elevated expression of GDI2 predicts poor prognosis in HCC patients, indicating that GDI2 could be applied as a predictive biomarker for diagnosis and prognosis of HCC.
基金:
Applied basic research program of Joint special of Science and Technology hall of Yunnan Province and Kunming Medical University [Number: 2017FE468(-104)]; Yunnan Provincial Key Laboratory of Clinical Virology [202005AG070062-013]; and Yunnan Digestive Endoscopy Clinical Medical Center Foundation for Health Commission of Yunnan Province [2020LCZXKF-XH06] and [2021LCZXXF-XH07] of [2X2019-01-02].
第一作者机构:[1]School of Medicine, Kunming University of Science and Technology, Affiliated by The First People's Hospital of Yunnan Province, Kunming 650504, Yunnan, China.[2]Yunnan Digestive Endoscopy Clinical Medical Center, Gastroenterology Department, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan, China.
通讯作者:
通讯机构:[1]School of Medicine, Kunming University of Science and Technology, Affiliated by The First People's Hospital of Yunnan Province, Kunming 650504, Yunnan, China.[2]Yunnan Digestive Endoscopy Clinical Medical Center, Gastroenterology Department, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650032, Yunnan, China.
推荐引用方式(GB/T 7714):
Zhang Wen,Liu Zhongjian,Xia Shilin,et al.GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma.[J].AGING-US.2021,13(23):25304-25324.doi:10.18632/aging.203748.
APA:
Zhang Wen,Liu Zhongjian,Xia Shilin,Yao Lei,Li Lan...&Sun Zhiwei.(2021).GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma..AGING-US,13,(23)
MLA:
Zhang Wen,et al."GDI2 is a novel diagnostic and prognostic biomarker in hepatocellular carcinoma.".AGING-US 13..23(2021):25304-25324